Grimanelli et al. identify VAPA as a key regulator of surfactant lipid trafficking in alveolar type 2 cells. VAPA interacts with ABCA3 at ER-lamellar body membrane contact sites, linking VAPA dysfunction to impaired lamellar body formation and syndromic lung disease in humans.
